# reload+after+2024-01-21 01:43:36.673878
address1§835 Industrial Road
address2§Suite 400
city§South San Francisco
state§CA
zip§94070
country§United States
phone§650 595 2595
fax§650 453 2410
website§https://www.atreca.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
fullTimeEmployees§90
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John A. Orwin M.B.A.', 'age': 58, 'title': 'President, CEO, Director & Principal Financial Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 927033, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Tito A. Serafini Ph.D.', 'age': 60, 'title': 'Founder, Chief Strategy Officer & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 665504, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen E. Gould Ph.D.', 'age': 58, 'title': 'Chief Scientific Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 380517, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rick  Ruiz', 'age': 59, 'title': 'Principal Accounting Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Courtney J. Phillips J.D.', 'age': 48, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Philippe C. Bishop M.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Roger Richard Ruiz', 'title': 'Vice President of Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§10
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.166
currency§USD
dateShortInterest§1702598400
forwardEps§-0.57
exchange§NMS
quoteType§EQUITY
shortName§Atreca, Inc.
longName§Atreca, Inc.
firstTradeDateEpochUtc§1561037400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e3625ee8-60d5-380c-9e65-767b5d9a5ca5
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§1.0
targetMeanPrice§4.0
targetMedianPrice§2.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§1.405
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
